OncoSil Medical gains TGA approval for pancreatic cancer device. The Australian Therapeutic Goods Administration has approved OncoSil's Class III medical device for treating unresectable locally advanced pancreatic cancer in combination with chemotherapy. The device is now listed on the Australian Register of Therapeutic Goods, enabling commercial launch across Australia where approximately 4,353 new pancreatic cancer cases occur annually. The company completed a manufacturing facility partnership with Cyclotek to scale production capabilities. OncoSil reported record dose sales and cash receipts in its latest update, secured an eight million dollar capital raise in February, and received a 1.84 million dollar R&D tax incentive refund. CEO Nigel Lange voluntarily reduced his fixed remuneration by ten percent, with compensation replaced through share issuance at 1.
Post from MarketNews_en
Log in to interact with content.